Zacks Investment Research
29 Jun 2026, 12:52 UTC · 1h ago
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
29 Jun 2026, 12:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Eli Lilly's obesity drugs, Zepbound and Foundayo, will be available via Medicare for $50 per month starting July 1, 2026. — Expanded access via Medicare typically increases patient volume and long-term revenue streams for high-demand obesity medications.
+0.60An EMA advisory committee recommended approving a label expansion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. — Label expansions increase the addressable patient population for a drug, enhancing long-term growth potential.
+0.40Eli Lilly is expected to report quarterly earnings of $9.01 per share (42.8% YoY) and revenues of $20.44 billion (31.4% YoY). — Strong projected growth in the bottom and top lines supports a bullish fundamental valuation.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares reached an all-time high following positive EMA recommendations and expanded access to obesity drugs.
The stock closed the last trading session higher and has shown positive returns over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
